ArticleEuropean journal of nuclear medicine and molecular imaging2026
The diagnostic value of [
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeWe aimed to explore the diagnostic value of [18F]F-NOTA-FAPI-FUSCC-07 ([18F]F-NOTA-FAPI) PET/CT in suspected recurrence ovarian cancer with CA125 dynamic rising but negative conventional imaging findings.
methodsForty-one suspected recurrent ovarian cancers who experienced [18F]F-NOTA-FAPI PET/CT for further diagnosis because of continuously rising CA125 value but negative conventional imaging (CT, MR or [18F]FDG PET/CT) findings were enrolled from June 2022 to January 2024. All conventional and [18F]F-FAPI PET/CT scans were performed in sequence within one week. Clinical characteristics, treatment data, [18F]F-NOTA-FAPI PET/CT findings, and survival outcomes were recorded. Differences in [18F]F-NOTA-FAPI PET/CT parameters across CA125 levels were analyzed using the Mann-Whitney U test.
results[18F]F-NOTA-FAPI PET/CT was positive in 34 patients (82.93%). Lesions were primarily peritoneal (85.29%), followed by lymph nodes (23.53%), stomach (8.82%), and small intestine (2.94%). Prior to imaging, median CA125 level was 51.90 (9.12–1586.00) U/mL, with a rising rate of 0.45 (0.02–44.42) U/mL/day and a doubling time of 56.28 (6.18-613.14) days. Detection rates were higher in the high-CA125 group (positive: 88.24%, negative: 11.76%) compared to the low-CA125 group (positive: 79.17%, negative: 20.83%). Notably, diagnostic performance was superior in patients with CA125 levels between 35 and 70 U/mL. Among 7 FAPI-negative patients, 3 were true-negative and 4 were false-negative. Disease relapse occurred in 30 patients (73.17%) after treatment, with a median PFS of 11.99 months (0-29.2). PFS differed significantly between FAPI-positive and FAPI-negative groups (p = 0.016).
conclusions[18F]F-NOTA-FAPI PET/CT demonstrated superior diagnostic performance in ovarian cancer patients with rising CA125 levels and negative conventional imaging findings, particularly in those with CA125 levels between 35 and 70 U/mL.
Indexed as
Identifiers
41848875What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.